About this trial
The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma.
The main questions it aims to answer are:
1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty? 2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma? 3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma?
Participants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.
Eligibility criteria
Qualifiers
Both sexes
≥ 16 years old, according the institutional protocols for new patients admittances.
histologically confirmed lung adenocarcinoma (LUAD)
Signed written informed consent form
Disqualifiers
A sample of peripheral blood that is not accessible.
Insufficient clinical pathological information in the electronic clinical record.
Withdrawal
Insufficient DNA quality and quantity for genomic sequencing analyses.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Oscar Gerardo Arrieta Rodríguez
Lead sponsor
Instituto Nacional de Cancerologia de Mexico
Sponsor institution